LONG MINI-FUTURE - AMGEN | Delayed Deutsche Boerse AG 19:03:19 31/05/2024 BST | ||
| 10.52 EUR | +1.35% |
|
| 1 month | +33.16% | ||
| 3 months | +27.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 10.52 | +1.35% |
| 30/05/24 | 10.38 | +5.81% |
| 29/05/24 | 9.81 | -2.29% |
| 28/05/24 | 10.04 | -7.72% |
| 27/05/24 | 10.88 | +1.40% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 07:03 pm
More quotesStatic data
| Product type | Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VV16X9 |
| ISIN | DE000VV16X94 |
| Date issued | 06/05/2022 |
| Strike | 190.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.84 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.92 € |
|---|---|
| Lowest since issue | 3.15 € |
| Spread | 0.29 € |
| Spread % | 2.66% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
305.8
USD
Average target price
316.3
USD
Spread / Average Target
+3.41%
- Stock Market
- Certificates
- Certificat
